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Interleukin-10 (IL-10) deficient dendritic cells (DCs) are potent antigen 
presenting cells during Chlamydia infection. To further understand the mechanism 
underlying this protective property in IL-10 DCs, we combined two proteomic 
techniques: 2DIGE and liquid chromatography mass spectrometry. We then performed 
western blotting on proteins from Chlamydia infected wild type (WT) and IL-10 knock 
out (KO) DCs. The results showed that alpha enolase (ENO1), a metabolic enzyme 
involved in the ninth step of glycolysis, was significantly upregulated in Chlamydia 
infected IL-10KO DCs compared to WT DCs. We further studied the role of ENO1 by 
silencing ENO1 gene using lentiviral siRNA technology. Flow cytometry, confocal 




also used to determine DC function. We then analyzed the effect of the ENO1 
knockdown on DC metabolism during Chlamydia stimulation.  
 The results showed that DC maturation and activation were decreased in ENO1 
knockdown DCs that were stimulated with Chlamydia compared to the Chlamydia 
stimulated WT DCs. In addition, pyruvate concentration decreased significantly in ENO1 
knockdown DCs stimulated with Chlamydia. The mitochondrial structure of Chlamydia 
stimulated ENO1 knockdown DCs appeared damaged compared to the Chlamydia 
stimulated WT DCs. The function of ENO1 in the immune response to Chlamydia 
trachomatis infection is unknown. However, the results from this study indicates that 
ENO1 may contribute to DC metabolism and mitochondrial homeostasis which may play 
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 Chlamydia trachomatis is the most frequently reported bacterial sexually 
transmitted infection in the United States (69). In 2014, 1.44 million new cases of 
Chlamydia were reported to Center for Disease Control (CDC) from 50 states and the 
District of Columbia (69). Chlamydia can cause severe health problems in women, such 
as pelvic inflammatory disease (PID), ectopic pregnancy, chronic pelvic pain, and 
infertility (1,2). Up to 40 percent of females with Chlamydia infections develop PID, and 
20 percent of those may become infertile (1). It is also important to note that Chlamydia 
infection increases the chance of contracting HIV (1, 2). Chlamydia infections also have 
a major economic impact in the US, with total annual costs of $16 billion in 2010 US 
dollars (69). Prevention strategies proposed against Chlamydia infection includes 
increased screening and massive treatment (3). There are racial and ethnic disparities in 
Chlamydial infection, with the disease being five times more prevalent among non-
Hispanic blacks compared to non-Hispanic whites (3). It is also estimated that 1 in 15 
sexually active females aged 14-19 years has contracted Chlamydia at one time or the 
other (4). However, recent epidemiologic data suggests that rapid treatment of infection 
prevents the development of some protective immunity against re-infections and that this 





effective vaccine against genital Chlamydia infection and indicate that the vaccine 
strategy is the most reliable and cost effective preventive method, having the greatest 
potential impact in controlling Chlamydia infections and the associated complications in 
the human population (7).  
A major challenge in Chlamydia vaccine development is that the experimental 
vaccines only have a partial and short term protective immunity against Chlamydia (6). 
Our lab has developed the IL-10 (interleukin 10) deficient dendritic cell system with 
distinct advantages for studies of therapeutic strategies and vaccine development (8). IL-
10 deficient bone marrow dendritic cells (BMDCs) stimulated with Chlamydia can confer 
a high level and long-term immunity against reinfection in female mice; and protect 
against the development of Chlamydia-induced tubal pathologies, specifically 
inflammation and infertility in vivo. IL-10 is a cytokine involved in immunoregulation 
and inflammation. IL-10 down regulates Th1 (T-helper cell 1) cytokine expression, MHC 
(major histocompatibility complex) class II antigens, and costimulatory molecules on 
dendritic cells (8, 9). It also enhances B-cell survival, proliferation, and antibody 
production (8). This remarkable ability of IL-10 deficient BMDCs indicates that they 
possess superior immunoregulatory properties required for inducing Chlamydia immunity 
(8, 9).  
The IL-10 deficient BMDC system therefore provides a suitable 
immunotherapeutic strategy to better define the immunologic and biochemical 
determinants and conditions for inducing an adequate and long-term immunity to protect 





administered, elicited in vivo, or administered separately to promote the induction of the 
appropriate and adequate immune response without any associated pathology (4). These 
immunomodulators could also be used in drug design protocols to shorten the duration of 
infection with the same beneficial effects. Therefore, studying the various mechanisms 
involved in host immunomodulation is needed in designing treatment strategies and an 
efficacious Chlamydia vaccine to prevent reproductive tract complications.  
Results from 2-DIGE Proteomics assay showed that alpha enolase (ENO1) was 
significantly up-regulated in Chlamydia pulsed IL-10 KO bone marrow dendritic cells 
after 2hr Chlamydia stimulation but not expressed in Chlamydia-pulsed WT BMDCs 
after 2hr incubation. Therefore, we hypothesized that the high level and early expression 
of alpha enolase (ENO1) may be involved in antigen uptake, internalization, and DC 
(dendritic cell) maturation. The central goal of this dissertation is to use our reliable 
experimental systems and state-of-the-art technological approaches to define the role of 
ENO1 in regulating the induction of protective immunity against Chlamydia, and 
determine its effect on DC mechanism of immunomodulation. Therefore, based on this 
hypothesis, we obtain the following aims: 
Aim 1: To confirm the dynamic distribution and expression of ENO1 in dendritic 
cells. 
Aim 2: To investigate the probable role of ENO1 in dendritic cell metabolism post-
Chlamydia infection.  









 Dendritic cells (DCs) originate from hematopoietic bone marrow progenitor cells 
(10). These progenitor cells undergo differentiation into immature dendritic cells (10). 
Immature dendritic cells continuously search their immediate environment for pathogens 
like bacteria and viruses (10, 11). Pattern Recognition Receptors (PPRs) like toll-like 
receptors (TLRs) contribute to detecting such pathogens (11, 12). TLRs distinguish 
detailed chemical patterns found on subsections of pathogens (10). Once an immature 
dendritic cell has come into contact with a presentable antigen, the DC becomes activated 
into a mature phase and commences to migrate through the lymphatic system and into the 
lymph node (12, 13). Immature dendritic cells phagocytose pathogens and degrade their 
proteins into fragments and, upon maturation, the DC then presents a portion of the 
fragment onto its cell surface using the major histocompatibility complex receptors (10, 
11). Simultaneously, they upregulate cell surface co-receptors such as cluster of 
differentiation (CD) CD86, CD80, and CD40 to significantly enhance DCs ability to 
activate T-cells. C-C motif chemokine receptor 7 (CCR7), a chemotactic receptor, is also 
upregulated and induces the dendritic cell to travel through the lymphatic system to a 
lymph node (13). Once in the lymph node DCs function as antigen presenting cells and 





pathogen combined with costimulatory signals which are not antigen specific (13). 
Dendritic cells can also induce T-cell tolerance (14). Certain C-type lectin receptors 
(CLRs) on dendritic cell surface, help direct dendritic cells function by instructing it to 
induce immune tolerance instead of lymphocyte activation (14).  
Every helper T-cell is specific to one particular antigen (14). Dendritic cells are 
able to activate a resting helper T-cell when the matching antigen is presented (15). 
Dendritic cells can activate both memory and naive T cells, and are the most effective at 
antigen presentation (15). Mature dendritic cells are able to activate CD8+ T antigen-
specific naive cells, the formation of CD8+ memory T cells necessitates the interaction of 
dendritic cells with CD4+ helper T cells (15).  In addition, CD4+ T cells activates the 
matured dendritic cells and authorizes them to proficiently induce CD8+ memory T cells 
(15).  Monocyte-derived dendritic cells can be generated in vitro from peripheral blood 
mononuclear cells (PBMCs) or stem cells from the bone marrow (16). Treatment of these 
cells with interleukin 4 (IL-4) and granulocyte-macrophage colony stimulating factor 
(GM-CSF) leads to differentiation to immature dendritic cells in about a week (16).  
I.I Dendritic Cells in Research 
The particular origin and development of the diverse subsets of dendritic cells and 
their effects on immunity is only slightly understood since dendritic cells are so rare and 
difficult to isolate (17). Dendritic cells are frequently in communication with neighboring 





of cell-surface receptors or via cytokines (17). Stimulating dendritic cells in vivo with an 
antigen causes it to rapidly begin producing IL-12 (18).  IL-12 is a signal that helps 
induce the naive CD4 T cells to differentiate into Th1 phenotype (18). The significance 
of antigen presentation function is preparing and activating the immune system to attack 
antigens that were presented on the surface of the dendritic cell (18). Various cytokines 
can be produced from dendritic cells that help for antigen presentation and recruitment of 
leukocytes (18).  
II.I  Dendritic Cell Metabolism  
Committed DC progenitors (CDPs) produce conventional DCs (cDCs) and 
plasmacytoid DCs (pDCs) (19). At present, very little is known about the metabolism of 
committed DC progenitors. However, the differentiation of human monocytes into DCs 
in response to granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
interleukin-4 (IL-4) is accompanied by increased expression of peroxisome proliferator-
activated receptor-γ (PPARγ) (20, 21). This is a key transcription factor regulating lipid 
metabolism, and PPARγ co-activator 1α (PGC1α) regulates mitochondrial biogenesis 
(22). Published data has shown that expression of PPARγ and PGC1α are followed by 
increased mitochondrial biogenesis (22). Furthermore, inhibiting mitochondrial 
respiration in monocytes by the electron transport chain (ETC) inhibitor rotenone, is able 
to block DC differentiation (22, 23). These studies prove that there is a close relationship 
between increased dendritic differentiation and citrate synthase activity (24). Citrate is 





or tricarboxylic acid cycle (TCA cycle) (24). Citrate is also a precursor of fatty acid 
synthesis (24). In fatty acid synthesis, citrate is exported from the mitochondria and 
converted into cytosolic Acetyl-CoA; which is an essential transitional component from 
glycolysis; and goes in to the TCA cycle and fatty acid synthesis (24).  
III.I Catabolic Process of Glucose  
Glucose is imported into the glycolytic pathway allowing it to be converted into 
pyruvate in the cytosol (25). Pyruvate then has two possible pathways to follow. In 
anaerobic conditions pyruvate is converted into lactate, which produces Nicotinamide 
adenine dinucleotide (NAD+) that is used for the production of Adenosine Tri Phosphate 
(ATP) during glycolysis (25).  Alternatively, in aerobic conditions, pyruvate can enter the 
mitochondria using mitochondrial pyruvate carrier 1 (MPC1), where it is converted into 
acetyl-CoA (25). The importance of this decision point in pyruvate metabolism pathways 
is indicated by the fact that it is regulated at many levels. Important enzymes involved in 
these processes are encoded by splice variants of transcripts of the pyruvate kinase 
muscle (PKM) gene (which encodes pyruvate kinase), and catalyzes the production of 
pyruvate from its precursor phosphoenolpyruvate (26). Oxidation of pyruvate in the 
mitochondria is stimulated by PKM1 (26). PKM2 stimulates the expression of hypoxia-
inducible factor 1α (HIF1α), which initiates the conversion of pyruvate into lactate by 
inducing of lactate dehydrogenase A (LDHA) expression (26, 27). In mitochondria, 
acetyl-CoA generated from pyruvate enters the TCA cycle leading to the production of 





dinucleotides (FADHs), which are utilized as substrates for the electron transport chain 
(ETC), and support oxidative phosphorylation (OXPHOS) and the production of ATP 
(25). Citrate can then be disseminated from the mitochondria to assist in the production 
of acetyl-CoA in the cytoplasm (28). Acetyl-CoA is needed for fatty acid synthesis, a 
process which is crucial for Toll-like receptor (TLR)-induced activation of DCs (28). 
IV.I      Dendritic Cell Resting Phase  
Cells at rest generate relatively deficient anabolic loads; the catabolism of 
multifaceted molecules has the ability to provide substrates for the TCA cycle within 
mitochondria (25). Catabolism of proteins and triacylglycerols provides amino acids and 
fatty acids, and generates ATP production through oxidative phosphorylation (OXPHOS) 
(25). Resting GM-CSF-induced bone marrow-derived DCs (BMDCs) have been shown 
to use fatty acid oxidation for OXPHOS (29). It is currently unclear whether resting cDCs 
or pDCs similarly undergo OXPHOS along with fatty acid oxidation, however resting 
BMDCs also ingest glucose (29). 
Based on previous studies, it is highly probable that dendritic cells utilize glucose 
to synthesize fatty acids which are then consequently oxidized (30). Previous research 
has proven that this process of glucose oxidation is crucial for the development of 
memory CD8+ T cells (30).  This process has also been shown to be beneficial to T cells 





concurrently with the glycolysis and fatty acid synthesis machinery which allows T cells 
to react more intensely in subsequent re-stimulation by an antigen (30).  
V.I Process of Dendritic Cell Activation 
The processing of glucose by glycolysis generates pyruvate needed to eventually 
produce substrates needed for the cell to undergo ATP synthesis (25). Mitochondrial 
pyruvate carrier 1 (MPC1) carries pyruvate into the mitochondria where it can be 
converted into acetyl-CoA (25). Acetyl-CoA then promotes the initiation of the TCA 
cycle (25). An alternative pathway is converting pyruvate to lactate under anaerobic 
condition. This process enables cells to harvest ATP when there is a limited supply of 
oxygen, this process is essential for cells to endure hypoxic environments (25). 
This pathway is often used in tumor cells even when there is an abundance of 
oxygen in the environment. The process of pyruvate being converted into lactate in the 
presence of oxygen is known as Warburg effect (31). Bone marrow dendritic cells show 
an increase in their consumption of glucose and an enhanced production of lactate (32). 
This process often occurs after the cells are stimulated with TLR agonist (32). This 
recently discovered observation reflects two modes of activation through metabolic 
changes (28, 31).  One form occurs early where there is an increase in flux through the 
glycolytic pathway in dendritic cells (31).  This early phase is followed by an alteration 
of the cellular metabolism, causing BMDCs to commit to the Warburg effect (28).  





and oxygen consumption made it possible for this process to be understood (33). When 
utilizing these new techniques to further understand DC metabolism, researchers 
observed that glycolysis is amplified within minutes of DC activation by various TLR 
agonist (28).  Studies have also proven that blocking glycolysis using 2-deoxyglucose (an 
inhibitor of hexokinase (HK)), the first enzyme in the glycolysis pathway, inhibits DC 
activation (28). This proves that glucose is an essential substrate needed to enhance the 
response of DCs to TLR agonists (25, 28). 
VI.I  Role of Glycolysis in Dendritic Cell Function 
The prompt upsurge in glycolysis which transpires in activated BMDCs is 
associated with an enhanced lactate production that does not reflect the Warburg effect 
since OXPHOS is an adequate source for generating ATP required for the cells (28). The 
transport of pyruvate by means of MPC1 into the mitochondria is vital for early 
activation of DCs (28). Therefore, one can imply that the main purpose of increased 
glycolysis appears to be to amplify pyruvate production in order to initiate the TCA 
cycle. This enables a transient upsurge in additional respiratory capacity (34, 35), giving 
rise to cells that are more metabolically proficient than resting BMDCs.  
It is probable that the increased respiratory capacity may point toward the fact that 
the cells have the capacity to use TCA cycle intermediates for other pathways within the 
cell (33). The main importance of the entrance of carbons derived from glucose into the 





inhibiting glycolysis post-transcriptionally effects the early stages of BMDCs activation, 
demonstrating that this pathway is necessary for the synthesis of proteins made in 
response to DC activation and not essential for gene expression downstream of TLRs 
(28). 
VII.I Late Dendritic Cell Activation Cause Metabolic Change 
TLR agonists that activate BMDCs for over 12 hours generally use the Warburg 
effect for the cells bioenergetic components. These cells normally contain small amounts 
of quantifiable mitochondrial oxygen consumption (25, 36). It is now understood that 
BMDCs’ obligation to the Warburg effect following activation is a response to the 
inhibition of the ETC by nitric oxide (NO) and the cellular expression of inducible nitric 
oxide synthase (iNOS) (36). Removal of functional OXPHOS by inhibition of the ETC 
by NO, causes BMDCs to be activated by TLR agonists (36).  These TLR agonists are 
dependent on glycolysis for the production of ATP (36). Understanding how NO 
production during inflammation has the capacity to inhibit OXPHOS is important (36).  It 
demonstrates that NO has the ability to impact pathogenic microorganism metabolism 
when they are reliant upon OXPHOS (36). 
When cDCs are activated by TLR agonists in vivo they display reduced 
mitochondrial activity and a boost in glycolysis for a long period needed for cell survival 





by autocrine type I interferon (IFN) signaling via hypoxia-inducible factor 1α (HIF1α) 
(37). 
VIII.I Regulation of Dendritic Cell Activation via glycolysis pathway 
Dendritic cells often display increased expression of maturation markers, such as 
CD40, CD80 and CD86 after DC stimulation (38). Additionally, in mouse BMDCs and in 
human monocyte-derived DCs, rapamycin selectively inhibits certain aspects of TLR-
driven DC activation and the expression of IL-6 and IL-10 (39, 40). 
Studies have also acknowledged a positive role for the mammalian target of 
rapamycin (mTOR) target hypoxia-inducible factor 1-alpha (HIF1α) in the TLR-induced 
activation of BMDCs (41, 42, 43).  HIF1 contains α- and β-subunits, and is typically 
considered to be activated through hypoxia. HIF1 has also been associated with 
stimulating glycolysis in several systems by promoting the expression of numerous 
enzymes associated with the glycolytic pathway (31).  Recent studies propose that the 
initial TLR-driven stimulation of glycolysis which transpires throughout DC activation 
does not need mTOR or HIF1α-mediated signaling (28, 44), and instead depends on 
protein kinase B (AKT) (35 ,45). TANK-binding kinase 1 (TBK1) and inhibitor of 
nuclear factor-κB kinase subunit-ε(IKKε) which initiates the activation of AKT 
downstream of TLRs (46).  AKT is essential because it phosphorylates and activates 
(Hexokinase 2) HK2 to assist with the structure of the mitochondrial surface (45, 47).  





blocked from associating with the mitochondria, it depletes the BMDCs ability to activate 
and react to TLR agonist (28). This signaling axis is significant for the longstanding 
obligation of DCs to glycolysis resulting from activation by TLR agonists (29, 33, 48).  
IX.I  Metabolic Signaling in Dendritic Cells 
Recent studies have shown that cellular metabolism is not the only foundation of 
generating ATP to promote DC differentiation and function, but also that proteins 
produced by metabolic pathways can act as signaling molecules to activate cellular 
responses. One illustration of this is provided by a significant recent discovery that in M1 
macrophages, HIF1α is activated by an intermediate within the TCA cycle called 
succinate which is produced from glutamate in cells dedicated to Warburg effect and 
contributes to IL-1β production (49).  Extracellular succinate is also capable of inducing 
DC activation by binding to the G protein-coupled receptor (GPCR) succinate receptor 1 
(50). Cellular concentrations of reactive oxygen species (ROS), a byproduct of ETC, are 
increased when the ETC is inhibited, which activates the nucleotide-binding 
oligomerization domain receptors (NOD-), leucine rich repeat (LRR-) and pyrin domain-
containing 3 (NLRP3) inflammasome, leading to the activation of caspase 1 and the 
production of IL-1β and IL-18 (51, 52).  TLR1, TLR2 or TLR4 agonist have the ability to 
induce this pathway promoting the activation of TNF receptor associated factor 6 
(TRAF6) and its relocation to the mitochondria (53).  While in the mitochondria it then 
interacts with evolutionary conserved signaling intermediate in Toll pathway (ECSIT) 





dendritic cell activation and for the ability of the cells to promote adaptive anti-tumor 
immunity (54).  
X.I Functions of Alpha Enolase 
Previous studies indicate that Burkitt lymphoma (BL), a high-grade B-cell 
malignancy, has a low expression of co-stimulatory molecules CD80 and CD86 on 
antigen-presenting cells (APCs), therefore inhibiting the activation of CD4+ T cells (55, 
56, 57). However, when the enolase-like protein in BL is inhibited, there is enhanced 
antigen presentation in B cells, macrophages and dendritic cells (58). Proteomics data 
from our lab showed an increase in ENO1 in IL-10 KO dendritic cells compared to WT 
cells (Figure 1 A). Previous data published from our lab also proves that IL-10 KO 
dendritic cells elicit high yield of Th2 (8, 9). Th2 was highly expressed in Chlamydia 
infected mice which rapidly cleared Chlamydia (8). This leads to the importance of 
understanding the role that enolase may have on the immune system.  
Phosphopyruvate hydratase (Enolase, Alpha Enolase 1 (ENO1)) discovered by 
Lohman and Mayerhof, is an enzyme highly involved in the glycolytic pathway (59).  
ENO1 is a multifunctional enzyme that aids in catalyzing the reversible conversion of 2- 
phosphoglycerate into phosphoenolpyruvate in the ninth step of the glycolysis pathway 
(59, 60). The ENO1 gene is one of the three enolase isoenzymes in mammals (59, 60).   
Each isoenzyme is a homodimer composed of 2 alpha, 2 beta and 2 gamma subunits (59, 





(60, 61).  ENO1 has the ability to function as a receptor and activator of plasminogen on 
the cell surface of several leukocytes and neurons (60, 62, 63).    ENO1 can also activate 
collagenases (enzymes that break down peptide bonds in collagen) and is expressed in 
mitogens, (which stimulate cell transformation and induce mitosis), cytokines, phorbol 
ester and bacterial lipopolysaccharide (LPS) endotoxin found in membrane of bacterial 
cell recognized by toll like receptor 4 (TLR4) in the innate immune response (60, 64) 
Alternative splicing of ENO1 results in a short isoform that enables it to bind to c-myc 
promoter and function as a tumor suppressor (65, 66, 67). ENO1 also interacts with the 
Notch1 receptor intracellular domain (N1IC) and down-regulates c-myc transcription, 






MATERIALS AND METHODS 
 
Culturing Bone Marrow Dendritic Cells (BMDCs): 
Materials: Complete Media: 500ml 1640 RPMI, MEM non-essential amino acid 
(100X) 10mM 5ml, MEM sodium Pyruvate solution (100X) 10nM 5ml, FBS 50ml, 2 
Mercaptoethanol (ME) .5ml, Gentamycin (50mg/ml) 1ml, L-glutamine (100X) 20mM 
5ml, Hepes buffer (1M) 5ml, Fungizone (250 ug/ml) 2ml, GM-CSF (10ng/ml) IL-4 
(5ng/ml). 
100X200mm plastic dishes, 5cc syringes, 25ga needles, 18-22ga needles, forceps, 
scissors, foam top, ethanol, package of 50ml tubes, 1%Hepes in 1640 RPMI mixture. 
Method: Sprayed area with 70% ethanol, euthanized mice using CO2 and cervical 
dislocation. Mounted the dead mice on dissection board stomach facing upwards and 
started cutting downwards from the torso of the mouse. With scissors closed, poked 
inside (gently) until femur is touched. Opened scissors and cut upwards (not cutting the 
femur) to remove the muscle. Removed femurs from mice, cleaned muscle, and placed 
femurs to 50ml tubes containing 1% Hepes in 1640 RPMI. Continued the extraction of 
the DCs under the tissue culture hood in the lab. Poured out 1% Hepes in 1640 RPMI 
mixture with bones in empty petri dish. Cleaned bones using forceps or scissors to 





Put cleaned bones in new petri dish with fresh 1% Hepes in 1640 RPMI. After all 
bones were cleaned they were placed in another empty petri dish and 10ml syringe with a 
gage of 25 was filled with 1% Hepes in 1640 RPMI and inserted into one of the femur 
ends. Femoral plug was removed by forcing media into the lumen of femur, until femur 
turned white. Cells were transferred into 50ml conical tubes. Plates were washed once to 
make sure that all cells were transferred. 1% Hepes in 1640 RPMI media was refluxed 
into tubes after centrifugation, until clumps were no longer visible using the 5ml electric 
pipette set at fast. Cells were washed 3 times with 1% Hepes in 1640 RPMI in 50ml tubes 
with 5ml of 1% Hepes in 1640 RPMI at 2500rpm at 4○ Celsius for 20min. After the first 
cells were transferred into a new 50ml tube. During the wash we would reflux the cells 
using the 1% Hepes in 1640 RPMI media and a 5ml pipette. We waited until bubbles 
were at the top of the pipette. Then pipetted the 1% Hepes in 1640 RPMI to the new 
conical tube slowly the capillary action causes the debris to remain stuck to the pipette. 
During the wash we created the complete media. We added a concentration of 5ng/ml of 
IL-4 and 10ng/ul of GM-CSF to the complete media created. The cells were counted and 
then transferred to cell culture dishes containing 12ml media at 2.67 x 107 cells. Plates 
are incubated for 3 days at 37○ Celsius and 5% CO2. On the third day plates are rocked 
back and forth media is discarded containing non-adherent cells. Then 10ml of media 
with GM-CSF& IL-4 was added and placed back into the incubator. On Day 5 dishes 
were scraped and non-adherent cells were transferred into new dishes and incubated for 
2hr. After 2hrs non-adherent cells were transferred into new dishes and placed back into 





scraping and placed into new dishes. These new dishes were re-labeled and placed back 
into the incubator for 7-10 days. After 7-10 days cells have differentiated into immature 
dendritic cells. 
 
Lentiviral Transfection of Dendritic Cells: 
Materials: ENO1-set Si RNA GFP, scrambled siRNA GFP, 6 well plates, 
polybrene, complete media, WT DCs 
Methods: Incubated cells at 37 degrees Celsius with 5% CO2 overnight in a 6 
well plate containing complete media without IL-4 and GM-CSF overnight prior to viral 
infection at a density of 0.3 X 106. Plates were spun at 2500 rpm for 20min. The media 
was removed from the wells by pouring off the supernatant and resuspending the cells 
with 2-3 ml of polybrene (8ug/ml) media mixture per well. 2ul of 106 IU/ml of virus was 
added to each well. One well was always left uninfected with virus as a control, and 1/3 
of the wells contained GFP scrambled virus as positive control. Cells were incubated for 
48hrs at 37○C with 5% CO2. Culture medium is then removed and spun at 2500rpm for 
20min then poured off. Cells were suspended with 1ml of complete medium in a 6 well 
plate and ready for use. 
 
Pulsing Dendritic Cells with Chlamydia muridarum: 
Materials: Chlamydia muridarum (MoPn), 6 well plates, 1.5ml centrifuge tubes 
Methods: Each plate contained specified amount of Chlamydia stimulation. The 





The calculated amount of bacteria culture was then added to wells according to specified 
times (less than 4hrs) starting with the longest time first and spinning plates between 
times at 2200rpm at 25°C. When incubated for longer than 4hrs, plates were spun for 1 
hour and incubated at 37°C 5%CO2 until ready. Cells were then scraped gently from all 
wells and transferred into 1.5ml centrifuge tubes and spun at 2500rpm for 20min at 4°C. 
Supernatant was collected and placed in -85°C for cytokine analysis. Cells were placed 
on ice and ready for use. 
 
Flow Cytometry: 
Materials: DC markers (conjugated antibodies with FITC, PE or 7AAD): CD3, 
CD4, CD13, CD29, CD39, CD45, CD54, CD70, CD80, CD83, CD86, CD95, CD102, 
CD119, CD120b, CD121a (IL-1R), CD217 (IL-17R), CD218a (IL18R), CD223 (MHC 
class II) CD265, CD298, CD305, TLR2, and TLR4, FACs Buffer, 5ml conical FACS 
tubes, 1.5ml tubes, foil, PBS and FBS 
Methods: After cells were stimulated with Chlamydia, cells are then resuspend in 500ul 
cold 2% FBS in PBS (wash buffer) and washed once in wash buffer, then spun at 
2200rpm for 5mins at 4°C. Cells were then resuspend in 100ul of wash buffer. Then 2.5ul 
of Fc blocker per 100ul of sample incubated for 10min at 4°C. Cells were then 
centrifuged at 2200rpm for 12min at 4 degrees Celsius. Supernatant was discarded and 
resuspended in 50ul. Surface markers and controls were then added to corresponding 
1.5ml Eppendorf tubes for 1hr in the dark at 4°C. Cells were washed twice using 500ul of 





and 500ul of wash buffer was added. Cells are then filtered into 5ml FACS tubes, 
covered with foil, and stored at 4°C until ready for reading on Guava EasyCyte or BD 
Accuri C6.  
 
Confocal Microscopy: 
Materials: Wash Buffer (500ml PBS in 10% BSA), 1.5 ml tubes, cold 1X PBS, 
primary antibodies and secondary antibodies, Fc Blocker, confocal dishes, cold poly-
lysine, glutaraldehyde, formaldehyde. 
Methods: After cells were pulsed, they were gently scraped from wells and 
transferred to 50ml or 15ml tubes. Cells were then centrifuged at 2200rpm for 15minutes. 
Supernatant was collected and placed in -85°C. Cells were then resuspended in wash 
buffer labeled in 1.5ml tubes. Cells were centrifuged at 2200rpm and washed two times at 
12min for 4 degrees Celsius and pour off supernatant. Cells were then Fixed by adding 
freshly made 4% formaldehyde in 0.01% glutaraldehyde in cold 1X PBS. The volume 
was maintained at around 200ul but was either increased or decreased depending on 
pellet size. Cells are then incubated for 5min at room temperature. Washed two times 
with 800ul of cold 1X PBS. Then cells were resuspended in 100ul adding 2.5ul of Block 
Fc receptor to each sample. Cells were then incubated for 10min at 4°C in the dark. 
Primary antibodies are then added and undergo incubation for 1hr at 4°C.  After the 
incubation period cells are then spun at 2200rpm for 12min at 4°C. Cells were then 
washed 2 times with wash buffer at 2200rpm for 12min at 4°C. During last wash 





DRAQ5 were added and incubated for 1hr at 4°C. Cells were then washed 3 times and on 
last wash 100ul of wash buffer was added and cells were now ready for viewing. Prior to 
preparing the cells, confocal dishes were labeled accordingly and coated with 1mL of 
cold poly-lysine and incubated overnight in the culture hood.  
 
Adoptive Transfer: 
Materials: Need 106 cells per mouse, BD 1ml TB Syringe with Intradermal 
Bevel Needle 26G, Depo-Provera,15ml tubes  
Methods: We used siRNA transfected DCs and WT DCs pulsed for only 2hrs 
with Chlamydia. Cells were scraped from 6well plates and placed into 15ml tubes then 
spun at 2500rpm for 20min at 4°C. Supernatant was collected and placed in -85°C. 
Complete media without IL-4 & GM-CSF was added to tubes to resuspend cells and 
count. There were 106 cells per 100ul of complete media. Cells were then placed on ice 
until ready. Depo-Provera was prepared at 25mg/ml using 100ul per mouse. In Center for 
Laboratory Animal Resources (CLAR) facility biohazard room inject mice with Depo-
Provera subcutaneously between ears. Intraperitoneal injection of cells at 106cells/100ul 
complete media from siRNA transfected groups pulsed with Chlamydia ENO1 
knockdown DCs and Scramble control DCs were added into mice according to respective 
cages. Likewise, WT DCs also pulsed with Chlamydia was added intraperitoneally to 
each mouse in respective cages at same concentration.  After 1 week mice were infected 
vaginally with MoPn and then swabbed vaginally every 3 days. Swabs were placed in -85 






 Materials: Syringe 40um filter MACS Buffer 50mL Tubes, 1X PBS Complete 
Media (without cytokines), RBC Lysis Buffer (10X) CAT#: 420301, 96 – well round 
bottom plate, MACS Separator, MACS LS Columns ϒ-irradiator, TC – 10 Cell Counter, 
Pan T Cell Isolation Kit II (MACS 130 – 095 – 130), XTT Cell Viability Kit (Cell 
Signaling #9095), 1.5 ml tubes, 1640 RPMI and 1% HEPES 
Methods: Cells were collected after DC cell culture and centrifuged at 2500rpm 
20min at 4°C then resuspended in 5mL of Complete Media. Cells were then counted ratio 
DC:TC = 1:5 CT:TC = 5:1 of DCs to T-cells were calculated for plating cells into round 
bottom 96 well plate. Cells were plated at 50μl of DCs at concentration of 1 x 105, 50μl 
of C. trachomatis (CT) at 25 x 105, and 50μl T – cells at concentration of 5 x 105. DCs 
were separated into 1.5ml tubes per CT infection. Non – UV DC’s were then separated 
spun at 2200rpm for 1hr at 25°C, then incubated at 1hr at 37°C. Infected media is then 
removed and resuspended in 200μl of complete media and put on ice. Now γ-irradiate all 
DCs with 2000rad for about 3min 10sec. Tubes were kept on ice until after T – cell 
harvest. 
 For T-cell harvest: Spleen was removed from mice and transported into 1640 
RPMI with 1% HEPES. A 40μm filter is placed on top of an empty 50mL conical tube 
and with syringe plunger.  The syringe plunger is then used to mash spleen into the filter, 
allowing the fluid to collect in the 50mL conical.  The filter is then rinsed with 1X PBS 
as often as needed. Cells are then spun at 1200rpm 10min 4°C and supernatant is 





1X PBS) and resuspended in pellet in 5mL of 1X RBC Lysis Buffer. Cells were then 
incubated at room temp for 4-5min. Next we added 20ml of 1X PBS to the solution and 
centrifuged at 1200rpm 10 min 4°C and remove supernatant then washed cells twice with 
1X PBS at 1200rpm for 10min 4°C. After last wash, cells were then resuspended in 
35mL 1X PBS and T – cells were counted.  
UV DC stimulation with T-cell: T-cells were then spun at 22000rpm for 1hr at 
25°C, and incubated for 1hr at 37°C. Cells were then resuspended in 40μl of MACS 
buffer per 107 total cells and added to 10μl of PAN T – Cell Biotin –Antibody Cocktail 
per 107 total cells. Cells were mixed well and incubated in the dark for 5min at 4°C. 30ul 
of MACS buffer was added per 107 total cells and 20μl of Anti-Biotin Micro Beads per 
107 total cells. Cells were mixed well and incubated in the dark for 10min at 4°C. The 
MACS LS Column was rinsed with 3ml of MACS Buffer and flow through was 
discarded. T-cell suspension was then added to column and flow through was collected. 
This flow through represented the enriched T – cells. Column was then washed one time 
with 3 mL of MACS buffer and combined with the previous collected flow through. Cells 
were spun at 1200rpm for 10min at 4°C and resuspended in 10mL of complete media 
then cells were counted. Cells were kept on ice until ready to use. After 2hrs of 
incubation at 37°C, supernatant was then removed and stored at -85°C, then resuspended 
in 200μl of complete media. T – cells are now added to the corresponding wells with UV-
DCs and bringing the volume to 250ul with complete media. Cells are incubated 5 days. 
On Day 5 150μl of the supernatant is removed and stored at -85°C. Cells were then ready 





volume ratio of XTT detection solution (Electron coupling solution: XTT Reagent). 50 μl 
of XTT detection solution was added per well and incubate at 37°C for 3hrs a 
spectrophotometer was then used to read at 450nm. 
 
 Infectivity Assay: 
Materials: Swabs, Transport Media (SPG media w/ T-Med), dry ice, 15ml tubes, 
beads 
Methods: Prepared Transport Media under hood by adding 2 beads per 15ml tube 
and 1.5ml of transport media per tube. Transport Media and a box with dry ice was 
brought into the CLAR facility Biohazard room.  Mice were swabbed vaginally Swab 
mice vaginally every 3 days until day 15. After day 15 mice were swabbed once every 
week. After each swab was placed in 15ml tube of Transport Media, the tube was then 
immediately placed on dry ice. Samples were transported back into the lab transporting 
and placed in 85°C until analyzing for infectivity rate. 
 
Fertility Assay: 
Materials: Male mice, scissors, needles 18-22 Ga, foam tops 
Method: With permission from CLAR facility place in corresponding cages, 1 
male mouse per 2 female mice. After 31 days (or when instructed by CLAR faculty) mice 







Western Blotting Analysis: 
Materials: Pierce BCA Protein Assay Kit, RIPA buffer, heat block, running 
buffer, transfer buffer, electrophoresis unit, TGX gels Bio-Rad, nitrocellulose paper, 
protein marker ladder, 5ml pipet, transfer apparatus, blocking buffer, TBST, shaker, 
primary antibodies, secondary antibodies, LAS – 4000 machine, Solution A and Solution 
B from Luminex (to detect bands), foil, PBS, forceps, box to hold membrane, Cy3 and 
Cy5. 
Method: Dendritic cell lysates were denatured, and then ran on TGX gels (Bio-
Rad) for 1hour. Proteins were then transferred on to nitrocellulose membrane (Bio-Rad) 
using wet transfer method. After 1 hour, blots were washed, blocked with 5% milk then 
incubated with primary antibody for ENO1 (from Abcam) overnight at 4°C. 
Subsequently, blots were washed three times in TBS/Tween followed by incubation of 
the HRP conjugated secondary Abs (R&D systems) and Amersham WB Cy3 secondary 
(GE Healthcare) for 1hr. Blots were washed and developed using Western ECL substrate 
and viewed in a Bio-Rad Gel Doc XR+ System. The images were saved as Tiff files.  
Modified Western Method: We followed the Cy5 Total Protein Normalization 
procedure as shown by McWhirter and colleagues (74). DC cell lysates were stained with 
Cy5 Amersham WB (GE Healthcare) for 30 min at room temperature and ran on TGX 
gels (Bio-Rad) for 1hour. Proteins were then transferred onto PVDF membrane (Bio-
Rad) using The Trans-Blot Turbo Transfer System (Bio-Rad) for 7 min. blots were 
washed, blocked with 5% milk then incubated with primary antibody overnight at 4°C. 





HRP conjugated secondary Abs (R&D systems). Blots were washed and developed using 
Western ECL substrate in Bio-Rad Gel Doc XR+System. Viewed using fluorescence for 
protein detection. Cy5 total protein normalization in Western blot analysis. 
 
Statistical analysis: 
The data derived from different experiments was analyzed and compared by 
performing a 1- or 2-tailed t-test.   Data presented as the mean ± SE of at least three 
independent experiments. The relationship between diverse experimental groups was 
evaluated by analysis of variance (ANOVA) (Microsoft Excel 2015 Redmond, WA).  







Dynamic Distribution of ENO1 
The results in Figure 1A indicate ENO1 protein levels were increased after IL-10 
KO DCs were stimulated with Chlamydia. Western blot and confocal microscopy 
analysis was performed to confirm the proteomics results (Figures 1B and 1C).  The 
confocal images confirmed the dynamic distribution of ENO1 in IL-10 KO DCs after 
Chlamydia stimulation. After confirming that ENO1 levels were maintained at high 
levels in IL-10 KO DCs after Chlamydia stimulation we proceeded by using lentiviral 
technology to successfully knockdown ENO1 completely in WT DCs after 48 hours 





 Figure 1A & B: ENO1 Expression in IL-10 KO DCs.   
A). Dendritic Cell lysates from WT DCs and IL-10 KO DCs stimulated with and without 
Chlamydia. The Cy5 represents red dye and Cy3 represents green dye. The red color 
indicates high expression of protein in IL-10 KO DCs while the green color indicates 
high expression of protein in WT DCs. The yellow color indicates that the protein 
expression is the same for both WT and IL-10 KO DCs. Table 1 in the figure above 
depicts spot numbers corresponding to differentially expressed proteins in proteomics 
image. Alpha enolase is shown in red font and is upregulated (>3.0 fold) in IL-10 KO 
DCs after 2 hours of Chlamydia stimulation. B).Western Blot analysis showed that after 2 














Figure 1C: Distribution of ENO1 in Dendritic Cells. 
Confocal microscopy analysis of ENO1 expression in WT and IL-10 KO DCs stimulated 
with Chlamydia.   The graph is a representation of the confocal images that express 
ENO1. There is a significant difference (p<0.05) in ENO1 expression between IL-10KO 
DCs and WT DCs regardless of Chlamydia stimulation. The confocal confirms that 
ENO1 is expressed most abundantly in the cytoplasm of the dendritic cell.  This 
experiment was repeated 3 times. This confirms that ENO1 is expressed most abundantly 

















Figure 2A: ENO1 knockdown Lentiviral Infection. 
ENO1 knockdown was used to knockdown ENO1 in WT DCs at 0 hours, 24 hours and 
48 hours. Scramble siRNA was used as a control for ENO1 knockdown confirmation.  
Western blot analysis confirms expression of ENO1 in DCs transfected with ENO1 
knockdown. ENO1 expression is present in siRNA Scramble control and ENO1 
knockdown 0 hour and 24 hour transfection. ENO1 expression is completely knocked 
down after 48hrs of transfection. Therefore, WT cells transfected with ENO1 knockdown 
at 48 hours will be used continually to further analyze ENO1 effects on Dendritic Cell 
function. This experiment was repeated 3 times. 
 
The Effect of ENO1 on DC Immunoregulation  
 In order to further understand the role of ENO1 in the metabolic regulation of 
DCs we measured the concentration of Pyruvate (Figure 3A). Pyruvate concentration was 
lower in ENO1 knockdown DCs compared to WT DCs. Due to lower concentration of 
pyruvate one can predict that ENO1 may regulate the metabolic pathways which have an 
effect on DC function since pyruvate is a crucial step eventually leading to the citric acid 
cycle and the electron transport chain which is responsible for high yield of ATP 
production needed for DC activation and maturation. Figure 3B indicates the modified 
protein analysis Figure 3C show proteins associated with mitochondrial function. ANT 
1/2/3/4 is responsible for mitochondrial export of ATP. ANT 1/2/3/4 show low 
expression in uninfected ENO1 knockdown DCs, but when stimulated with Chlamydia 
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this expression increases. While in WT DCs the expression of ANT 1/2/3/4 remains 
consistent with or without Chlamydia stimulation.  Translocase outer membrane (TOM) 
20 expression is low in ENO1 knockdown DCs stimulated with Chlamydia. While in WT 
DCs, TOM20 expression remains constant regardless of Chlamydia stimulation. BAX 
(BCL-2 associated X protein) is highly expressed in unstimulated ENO1 knockdown 
DCs, yet is not expressed in Chlamydia stimulated ENO1 knockdown DCs. BAX 
expression is low in WT DCs with or without Chlamydia stimulation. BCL-2 expression 
is low in ENO1 knockdown DCs unstimulated and is not expressed in ENO1 knockdown 
DCs. BCL-2 is not expressed in WT DCs unstimulated or stimulated with Chlamydia. 
Cytochrome C is highly expressed in ENO1 knockdown DCs unstimulated with 
Chlamydia and is not expressed in ENO1 knockdown DCs stimulated with Chlamydia. 
While in WT DCs Cytochrome C is expressed in unstimulated DCs and not expressed in 
Chlamydia stimulated DCs. This may indicate that the mitochondrial structure is much 
less intact when ENO1 knockdown in the cells. In order to observe the cells undergoing 
apoptosis we use flow cytometry to observe apoptotic events (Figure 3D). It was evident 
that apoptosis was decreased after DCs were stimulated with Chlamydia but there was a 
significant increase in ENO1 knockdown DCs verses WT DCs.  
This means that ENO1 knockdown DCs may have a less efficient antigen 
presenting function.  We then proceeded to using transmission electron microscopy 
(TEM) to view the mitochondrial structure (Figure 3E). We discovered that the 
mitochondrial membrane structure in ENO1 knockdown DCs was highly permeable and 




DCs. Mitochondrial structural changes have been known to affect the production of ATP 





Figure 3A: Pyruvate Concentration in Chlamydia stimulated Dendritic Cells. 
Pyruvate concentration was obtained in cell lysate and supernatant. Pyruvate 
concentration was measured using spectrophotometer. Concentration of pyruvate is 
shown post-Chlamydia stimulation at 0min, 30min, 60min, 120min, and 240min. There is 
a significant difference (p<0.05) of high concentration of Pyruvate at 30min, 120min and 
240min. This graph shows that ENO1 knockdown DCs stimulated with Chlamydia 










Figure 3B: Pyruvate Dehydrogenase Expression in DCs. 
Proteins which were normalized using ImageQuant Reader (GE Healthcare).  The total 
protein was detected and used for normalization using Cy5 dye and proteins of interest 
were probed using Cy3 secondary from the Amersham System Protocol (GE Healthcare).  
The ratio of Cy3/Cy5 indicates the differentially expressed proteins.  The expression of 











Figure 3C: Mitochondrial Structure. 
Transition electron microscopy (TEM) technology indicates the structural difference of 
the mitochondria using. The depiction shows WT and ENO1 knockdown DCs 
unstimulated and stimulated with Chlamydia for 13hrs. After stimulation the red arrows 
indicate a major morphology change of mitochondria in ENO1 knockdown DCs. The 









Figure 3D: Expression of Mitochondrial Associated Proteins. 
Proteins which were normalized using ImageQuant Reader (GE Healthcare).  The total 
protein was detected and used for normalization using Cy5 dye and proteins of interest 
were probed using Cy3 secondary from the Amersham System Protocol (GE Healthcare).  
The ratio of Cy3/Cy5 indicates the differentially expressed proteins.  Cytochrome C, 
BAX, TOM 20 all had lowered expression in chlamydia stimulated DCs with their ENO1 







 Figure 3E: Apoptosis Analysis. 
Analysis of apoptotic events using Flow Cytometry analysis with the FITC Annexin V 
Apoptosis Detection Kit with 7-AAD (Biolegend). The Green-B Fluorescence is FITC 
detection and Red-B Fluorescence is 7-AAD detection.  DCs were stained with CD11c 
Pey-CY7 stain and gated for further analyzation. Quadrant 1(top left) Quadrant 2(top 
right), Quadrant 3(lower left), Quadrant 4(lower right). Cells in Quadrant 1 indicates 
necrosis pathway while cells in Quadrant 3 are live cells. Cells in Quadrant 4 indicate 
cells undergoing apoptosis. Chlamydia stimulation for ENO1 knockdown DCs and WT 
DCs undergo less apoptotic events. But Chlamydia stimulated ENO1 knockdown DCs 
undergo significantly high expression (p<0.05) of apoptosis events verses Chlamydia 
stimulated WT DCs. Experiment was repeated 3 times. 
 
ENO1 knockdown DCs regulates DC activation and maturation 
It is clear that ENO1 may have an effect on DC function therefore we observed 
DC surface markers involved in maturation and activation. (Figure 4A) indicates that the 
expression of TLR4 is significantly lower in infected WT DCs compared to Chlamydia 
stimulated ENO1 knockdown DCs. MHC II antigen presenting receptor is a crucial DC 
receptor for antigen presentation during Chlamydia infection. MHC II and CD80 (a co-




WT DCs, although CD40 expression in infected ENO1 knockdown DCs was higher than 
in infected WT DCs. This indicates that ENO1 has an effect on DC maturation. Lowered 
DC maturation results in lower DC activation to Th1 cells associated with rapid clearance 
of Chlamydia infection. It is clear that ENO1 may have an effect on DC function 
therefore we observed DC surface markers involved in maturation and activation. Figure 
3a indicates that the expression of TLR4 is significantly lower in infected WT DCs 
compared to infected ENO1 knockdown DCs. Figure 4B demonstrates that during 
Chlamydia infection ENO1 knockdown DCs expression of Th1 cytokines IL-12, MIP-
1beta, MIP-1alpha, and RANTES were significantly lowered in comparison Chlamydia 
infected WT DCs while simultaneously showing increase in Th2 cytokines IL-10 and IL-
14.  DC – T cell co-culture is demonstrated in Figure 4C and 4D. Figure 4C shows that 
Th1 cytokines RANTES, IL-1beta, IL-1alpha, and IL-9 were significantly lowered while 
Th2 cytokines IL-13, IL-17A, IL-10, and IL-5 were highly expressed infected ENO1 
knockdown DCs.  Figure 4D also indicates lower total t-cell proliferation in ENO1 






Figure 4A: Dendritic Cell Maturation Markers. 
Figure 4 is a flow cytometry analysis using BD Accuri C6 analyzer showing Toll Like 
Receptor 4 (TLR4) expression. DCs were stained with CD11c Pey-CY7 stain and gated 
for further analyzation. Cells were stained with FITC conjugated TLR4. Samples were 
repeated 3 times. TLR4 expression was significantly lowered in ENO1 knockdown DCs 
stimulated with Chlamydia in comparison to WT DCs stimulated with Chlamydia. TLR4 
expression is significantly lower in unstimulated ENO1 knockdown DCs verses 
unstimulated WT DCs. Flow Cytometry analysis using Guava EasyCyte flow cytometer 
showing CD80, CD40, MHC II, CD86 expression in DCs stained with CD11c Pey-CY7 
gated for further analyzation. Cells were stained with FITC conjugated MHC II, FITC 
conjugated CD80, FITC Conjugated CD40 and PE Conjugated CD86. Samples in double 
stained with PE and FITC were compensated. Green-B-Fluorescence indicates FITC 
staining and Yellow-B Fluorescence indicates PE staining. Samples were repeated 3 
times.  The graph depicts the flow cytometry dot plot data showed significant differences 
(p<0.05) between WT DCs and ENO1 knockdown DCs.  The expression of CD86, CD80 
and MHC II were lower in ENO1 knockdown DCs after Chlamydia stimulation vs. WT 
DCs. While CD40 expression increased expression in ENO1 knockdown DCs stimulated 
with Chlamydia. TLR4 expression is significantly lower in unstimulated ENO1 





Figure 4B: Dendritic Cell Cytokine Expression. 
Bio-Plex Pro Mouse Cytokine 23-Plex multiplex array was used for cytokine analysis 
according to manufacturer’s guidelines (Bio-Rad). Cytokines IL-4, IL-17A, IL-10, IL-1 
alpha, IL-1 beta, IFN-gamma, TNF alpha, MCP-1 IL-12(p70), MIP-1alpha, MIP-1beta, 
RANTES which induce T-helper cell 1 response. At 1hr Chlamydia stimulation there is a 
significant (p<0.05) increase of IL-12(p70), MIP-1alpha, MIP-1beta, and RANTES in 
WT DCs verses ENO1 knockdown DCs. There is a significant (p<0.05) increase of IL-10 










Figure 4C & D: DC Antigen Presenting Function and T-cell Proliferation 
C). There is a low expression of RANTES, IL-1beta, IL-1alpha and IL-9 cytokines in 
ENO1 knockdown DCs co-cultured with T-cells verses WT DCS co-cultured with T-
cells. These cytokines aid in the induction of T helper cell 1(Th1) response. IL-13, IL-10 
and IL-15, IL-17A show high expression in ENO1 knockdown DCs co-cultured with T-
cells in comparison to WT DCs co-cultured with T-cells. D). The T-cells were collected 
from spleen of Chlamydia infected WT mice and co-cultured with WT DCs and ENO1 
knockdown DCs. ENO1 knockdown DCs showed less T-cell proliferation in comparison 
to WT DCs. 
 
 
The Effect of ENO1 on DC function in vivo 
We performed adoptive transfer of ENO1 knockdown DCs into C57/BL6 mice 
via tail intravenous injection. This adoptive transfer was repeated multiple times.  
However, due to the inability to completely restrain the mice, we believe that the 
intravenous injection of the ENO1 knockdown DCs may not have been performed 
optimally or maybe the amount of cells used was not sufficient. Therefore, only 3 dates 
gathered from the infectivity analysis were statistically significant.  Although Figure 5A 




Chlamydia infection throughout term. While Chlamydia stimulated WT DC mice cleared 
Chlamydia at a faster rate. 
 
Figure 5A: ENO1 knockdown DCs Infectivity assay. 
Graph shows WT mice with Chlamydia stimulated ENO1 knockdown DCs (ENO1 
knockdown DCs) and WT mice with Chlamydia stimulated WT DCs, and WT mice with 
no DCs adoptively transferred. This data shows significant decrease (p<0.05) in 
Chlamydia infection at 15, 21, and 28 days post-Chlamydia stimulation in comparison to 








 Understanding the importance of ENO1 as it relates to the dendritic cell function 
and activation is still ongoing. It is important to note that the proteomics data shows 
several molecules which may also contribute to the increase in antigen presenting 
function of IL-10 KO DCs. ENO1 is one of the three isotypes of the enolase family and 
has been shown to play a role in inflammation (72). It is understood that plasminogen is a 
ligand for ENO1 membrane bond receptors (73) and confocal analysis has proven that 
there is a dynamic distribution of ENO1 on the surface of dendritic cells. Therefore, the 
inflammatory responses in Chlamydia may also be triggered by the effect of plasminogen 
on these receptors. We observed that TLR4 and co stimulatory cytokines CD80 and 
CD86 decreased in expression after ENO1 knockdown DCs were stimulated with 
Chlamydia. This implicates that when dendritic cells are stimulated with Chlamydia and 
ENO1, a key glycolytic enzyme is not present, the cells ability to produce high yields of 
ATP in the TCA cycle is decreased. This would affect the rate of maturation thereby 
decreasing DC activation and antigen presenting function. Interestingly, the inhibition of 
ENO1 contributes to increase in cytokines which are associated with activing Th1, which 
proves that ENO1 has some effect on DCs ability to activate Th2. Th2 is known to 





dendritic cell ability to activate Th2 cells needed in clearing the infection.  Even when 
DCs are co-stimulated with total T-cells collected from spleen of Chlamydia infected 
mice cytokines associated with Th2 activation were still lowered when ENO1 was 
knocked down in these dendritic cells. Because ENO1 is a glycolytic enzyme it was 
important to understand the role that ENO1 has on mitochondria which is the location of 
TCA cycle and plays important role in apoptosis of the cell. When dendritic cells are 
deficient in ENO1 it is clear that the function of the mitochondria is disrupted. Therefore, 
pyruvate which is produced through the process of glycolysis, is inhibited leading to 
decrease expression of enzymes needed to undergo the TCA cycle as well as enzymes 
needed to maintain the structure of the mitochondria. Disrupting these mechanisms may 
in fact contribute to the decrease in antigen presenting function and maturation, since it 
was previously stated that ATP is essential in contributing to the proteins needed for 
these processes. ENO1 has several functions as described that may also be contributing to 
the change in DC function after stimulation. ENO1 may also serve as a target for therapy 
in lowing inflammation that are dependent on the expression of Th2.  Alpha Enolase is 
highly expressed throughout the cell and has numerous functions, therefore it is important 
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